Mark Bodmer's most recent trade in Evelo Biosciences Inc was a trade of 6,625 Restricted Stock Units done . Disclosure was reported to the exchange on Aug. 7, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Evelo Biosciences Inc | Mark Bodmer | CSO, President of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2023 | 6,625 | 13,250 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | Mark Bodmer | CSO, President of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2023 | 6,625 | 19,752 (0%) | 0% | - | Common Stock | |
| Evelo Biosciences Inc | Mark Bodmer | CSO, President of R&D | Sale of securities on an exchange or to another person at price $ 9.51 per share. | 07 Aug 2023 | 3,128 | 16,624 (0%) | 0% | 9.5 | 29,747 | Common Stock |
| Evelo Biosciences Inc | Mark Bodmer | CSO, President of R&D | Sale of securities on an exchange or to another person at price $ 0.14 per share. | 23 May 2023 | 22,571 | 262,557 (0%) | 0% | 0.1 | 3,201 | Common Stock |
| Evelo Biosciences Inc | Mark Bodmer | CSO, President of R&D | Sale of securities on an exchange or to another person at price $ 0.13 per share. | 08 May 2023 | 68,014 | 285,128 (0%) | 0% | 0.1 | 8,536 | Common Stock |
| Evelo Biosciences Inc | Mark Bodmer | CSO, President of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2023 | 132,500 | 353,142 (1%) | 0% | - | Common Stock | |
| Evelo Biosciences Inc | Mark Bodmer | CSO, President of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2023 | 132,500 | 397,500 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | Mark Bodmer | CSO, President of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 530,000 | 530,000 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | Mark Bodmer | CSO, President of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Evelo Biosciences Inc | Mark Bodmer | CSO, President of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2021 | 179,000 | 179,000 | - | - | Stock Option (Right to Buy) |